Trial Profile
Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 02 Jul 2023
Price :
$35
*
At a glance
- Drugs Lisavanbulin (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Basilea Pharmaceutica
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 30 Sep 2022 Status changed from active, no longer recruiting to discontinued.
- 16 May 2022 Planned End Date changed from 1 Sep 2022 to 1 Aug 2022.